JP2014525435A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525435A5
JP2014525435A5 JP2014527791A JP2014527791A JP2014525435A5 JP 2014525435 A5 JP2014525435 A5 JP 2014525435A5 JP 2014527791 A JP2014527791 A JP 2014527791A JP 2014527791 A JP2014527791 A JP 2014527791A JP 2014525435 A5 JP2014525435 A5 JP 2014525435A5
Authority
JP
Japan
Prior art keywords
composition
rnai agent
hsf1
nucleotides
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/054455 external-priority patent/WO2013030778A2/en
Publication of JP2014525435A publication Critical patent/JP2014525435A/ja
Publication of JP2014525435A5 publication Critical patent/JP2014525435A5/ja
Pending legal-status Critical Current

Links

JP2014527791A 2011-09-02 2012-08-30 Ｈｓｆ１関連疾患を処置するための有機組成物 Pending JP2014525435A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530532P 2011-09-02 2011-09-02
US61/530,532 2011-09-02
US201261598453P 2012-02-14 2012-02-14
US61/598,453 2012-02-14
PCT/IB2012/054455 WO2013030778A2 (en) 2011-09-02 2012-08-30 Organic compositions to treat hsf1-related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018168244A Division JP2019001813A (ja) 2011-09-02 2018-09-07 Ｈｓｆ１関連疾患を処置するための有機組成物

Publications (2)

Publication Number Publication Date
JP2014525435A JP2014525435A (ja) 2014-09-29
JP2014525435A5 true JP2014525435A5 (enExample) 2015-10-15

Family

ID=47143967

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014527791A Pending JP2014525435A (ja) 2011-09-02 2012-08-30 Ｈｓｆ１関連疾患を処置するための有機組成物
JP2018168244A Pending JP2019001813A (ja) 2011-09-02 2018-09-07 Ｈｓｆ１関連疾患を処置するための有機組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018168244A Pending JP2019001813A (ja) 2011-09-02 2018-09-07 Ｈｓｆ１関連疾患を処置するための有機組成物

Country Status (11)

Country Link
US (3) US20160032284A1 (enExample)
EP (3) EP3521432A1 (enExample)
JP (2) JP2014525435A (enExample)
KR (1) KR20140057374A (enExample)
CN (1) CN103930547A (enExample)
AU (1) AU2016202437B2 (enExample)
BR (1) BR112014005103A2 (enExample)
CA (2) CA3185394A1 (enExample)
EA (1) EA201490553A1 (enExample)
MX (1) MX2014002536A (enExample)
WO (1) WO2013030778A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス， インコーポレイテッド 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
CA3002819A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US11095153B2 (en) 2019-03-15 2021-08-17 Ossia Inc. Wireless power system technology implemented in lighting infrastructure
US20210380988A1 (en) * 2020-05-13 2021-12-09 University Of Massachusetts Reducing Prominin2-Mediated Resistance to Ferroptotic Cell Death
WO2022006436A2 (en) * 2020-07-01 2022-01-06 Bioaffinity Technologies, Inc. Compositions and methods for cellular delivery of rna
CN119523991B (zh) * 2024-12-06 2025-09-05 湖南师范大学 表木栓醇在制备抗肺癌物质中的用途和抗肺癌组合物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7053052B2 (en) 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
CA2451247A1 (en) 2001-06-22 2003-01-03 The Regents Of The University Of California Eukaryotic genes involved in adult lifespan regulation
EP1424998B1 (en) 2001-08-16 2010-05-26 The Trustees of The University of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
KR20050084607A (ko) 2002-09-28 2005-08-26 매사추세츠 인스티튜트 오브 테크놀로지 인플루엔자 치료제
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
CA2506714A1 (en) 2002-11-26 2004-06-10 University Of Massachusetts Delivery of sirnas
WO2004064731A2 (en) 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
CN101291653B (zh) 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
NZ545360A (en) 2003-08-28 2009-06-26 Novartis Ag Interfering RNA duplex having blunt-ends and 3'-modifications
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CN101184839A (zh) 2005-04-08 2008-05-21 纳斯泰克制药公司 用于呼吸道病毒感染的RNAi治疗
US8354384B2 (en) 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
WO2007041294A2 (en) * 2005-09-29 2007-04-12 The Trustees Of Boston University Methods for sensitizing cancer cells to inhibitors
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US7919603B2 (en) 2005-12-19 2011-04-05 New York University Heat shock RNA
EP2002004B1 (en) 2006-03-23 2015-10-14 Roche Innovation Center Copenhagen A/S Small internally segmented interfering rna
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008022035A2 (en) 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7858592B2 (en) 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
WO2008141074A1 (en) 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases
US8314227B2 (en) 2007-05-22 2012-11-20 Marina Biotech, Inc. Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2238251B1 (en) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
WO2010135669A1 (en) * 2009-05-22 2010-11-25 Sabiosciences Corporation Arrays and methods for reverse genetic functional analysis
CN102573914B (zh) 2009-10-16 2016-06-29 大学健康网络 卟啉纳米囊泡
CA2784783C (en) 2009-12-18 2021-07-20 Novartis Ag Organic compositions to treat hsf1-related diseases
KR101733096B1 (ko) 2015-09-25 2017-05-24 강건우 전자레인지용 밥솥

Similar Documents

Publication Publication Date Title
JP2014525435A5 (enExample)
JP2015517466A5 (enExample)
Gurunathan et al. A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes
Douglas et al. Splicing therapy for neuromuscular disease
Gorantla et al. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status
Fang et al. Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy
JP2015503608A5 (enExample)
JP2013525332A5 (enExample)
JP2013514321A5 (enExample)
Zhang et al. MicroRNA-25 negatively regulates cerebral ischemia/reperfusion injury-induced cell apoptosis through Fas/FasL pathway
Huang et al. Orally targeted galactosylated chitosan poly (lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis
Giger et al. Biomedical applications of bisphosphonates
JP2023093644A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
AU2013318338B2 (en) Method of treating cancer
JP2022115999A (ja) 浮遊病原体および刺激物に対して防御するための組成物および方法
Asl et al. Nano drug-delivery systems for management of AIDS: liposomes, dendrimers, gold and silver nanoparticles
JP6721252B2 (ja) 皮膚Ｔ細胞リンパ腫（ＣＴＣＬ）を処置するためのｍｉＲ−１５５阻害剤
JP2014518275A5 (enExample)
JP7291418B2 (ja) Ｐｃｓｋ９を標的としたアンチセンス核酸
JP2014528474A5 (enExample)
JP2019503199A5 (enExample)
AR079494A1 (es) Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1
WO2019209764A2 (en) Exon skipping oligomers and oligomer conjugates for muscular dystrophy
TW202300647A (zh) 用於治療多囊腎病之組成物
Cockcroft et al. Are inhaled longacting β2 agonists detrimental to asthma?